Nanexa AB (publ) (NANEXA.ST)
SEK 2.54
(-5.22%)
SEK 2.54
(-5.22%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 132.25 Million SEK | -22.29% |
| 2022 | 170.19 Million SEK | 3.15% |
| 2021 | 164.99 Million SEK | 207.31% |
| 2020 | 53.69 Million SEK | 51.51% |
| 2019 | 35.43 Million SEK | 27.02% |
| 2018 | 27.89 Million SEK | -15.88% |
| 2017 | 33.16 Million SEK | 61.08% |
| 2016 | 20.58 Million SEK | 164.18% |
| 2015 | 7.79 Million SEK | 201.32% |
| 2014 | 2.58 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 114.44 Million SEK | -7.63% |
| 2024 Q1 | 123.9 Million SEK | -6.31% |
| 2023 Q2 | 140.83 Million SEK | -9.47% |
| 2023 Q4 | 132.25 Million SEK | 5.71% |
| 2023 FY | 132.25 Million SEK | -22.29% |
| 2023 Q1 | 155.56 Million SEK | -8.59% |
| 2023 Q3 | 125.11 Million SEK | -11.16% |
| 2022 Q2 | 146.7 Million SEK | -4.43% |
| 2022 Q3 | 130.07 Million SEK | -11.34% |
| 2022 FY | 170.19 Million SEK | 3.15% |
| 2022 Q4 | 170.19 Million SEK | 30.85% |
| 2022 Q1 | 153.51 Million SEK | -6.96% |
| 2021 Q3 | 175.06 Million SEK | -13.9% |
| 2021 Q1 | 78.79 Million SEK | 46.75% |
| 2021 Q2 | 203.32 Million SEK | 158.05% |
| 2021 FY | 164.99 Million SEK | 207.31% |
| 2021 Q4 | 164.99 Million SEK | -5.75% |
| 2020 Q4 | 53.69 Million SEK | -13.33% |
| 2020 FY | 53.69 Million SEK | 51.51% |
| 2020 Q2 | 65.37 Million SEK | -8.44% |
| 2020 Q1 | 71.4 Million SEK | 101.5% |
| 2020 Q3 | 61.95 Million SEK | -5.24% |
| 2019 Q2 | 41.24 Million SEK | -4.43% |
| 2019 Q3 | 38.6 Million SEK | -6.41% |
| 2019 FY | 35.43 Million SEK | 27.02% |
| 2019 Q4 | 35.43 Million SEK | -8.19% |
| 2019 Q1 | 43.15 Million SEK | 54.7% |
| 2018 Q3 | 25.91 Million SEK | -9.25% |
| 2018 FY | 27.89 Million SEK | -15.88% |
| 2018 Q1 | 30.38 Million SEK | -8.37% |
| 2018 Q2 | 28.55 Million SEK | -6.03% |
| 2018 Q4 | 27.89 Million SEK | 7.65% |
| 2017 Q4 | 33.16 Million SEK | 105.12% |
| 2017 FY | 33.16 Million SEK | 61.08% |
| 2017 Q3 | 16.16 Million SEK | -8.33% |
| 2017 Q2 | 17.63 Million SEK | -9.12% |
| 2017 Q1 | 19.4 Million SEK | -5.74% |
| 2016 FY | 20.58 Million SEK | 164.18% |
| 2016 Q1 | 6.6 Million SEK | -15.26% |
| 2016 Q2 | 24.52 Million SEK | 271.34% |
| 2016 Q4 | 20.58 Million SEK | -5.67% |
| 2016 Q3 | 21.82 Million SEK | -10.99% |
| 2015 FY | 7.79 Million SEK | 201.32% |
| 2015 Q3 | 8.47 Million SEK | -22.61% |
| 2015 Q4 | 7.79 Million SEK | -8.06% |
| 2015 Q2 | 10.95 Million SEK | 0.0% |
| 2015 Q1 | - SEK | -100.0% |
| 2014 FY | 2.58 Million SEK | 0.0% |
| 2014 Q4 | 2.58 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AcuCort AB | 58.5 Million SEK | -126.053% |
| AlzeCure Pharma AB (publ) | 32 Million SEK | -313.29% |
| BioGaia AB (publ) | 2.33 Billion SEK | 94.331% |
| Enzymatica AB (publ) | 125.91 Million SEK | -5.04% |
| Enorama Pharma AB (publ) | 34.38 Million SEK | -284.636% |
| Gabather AB (publ) | 2.93 Million SEK | -4403.132% |
| Klaria Pharma Holding AB (publ.) | 73.12 Million SEK | -80.877% |
| Moberg Pharma AB (publ) | 634.73 Million SEK | 79.163% |
| Newbury Pharmaceuticals AB (publ) | 90.87 Million SEK | -45.544% |
| ODI Pharma AB | 12.27 Million SEK | -977.451% |
| Orexo AB (publ) | 786.6 Million SEK | 83.186% |
| Probi AB (publ) | 1.55 Billion SEK | 91.469% |
| Swedencare AB (publ) | 9.52 Billion SEK | 98.611% |
| Swedish Orphan Biovitrum AB (publ) | 74.02 Billion SEK | 99.821% |
| Toleranzia AB | 160.42 Million SEK | 17.559% |
| Vivesto AB | 355.87 Million SEK | 62.836% |